Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Slides:

Advertisements

Similar presentations

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.

Advertisements

2002 Air Medical Transport Industry Awards Air Medical Journal Volume 22, Issue 2, Pages (March 2003) DOI: /S X(03) Copyright.

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

Rhona Stein, Ph.D., David M. Goldenberg, Sc.D., M.D. CHEST

Air Pollution and Chest Disease

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

Clopidogrel-Induced Systemic Inflammatory Response Syndrome

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

A review of PCSK9 inhibition and its effects beyond LDL receptors

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Observers in the Medical Setting

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Short Total Sleep Time and Elevated Central Apnea Index are Significant Predictors of Coronary Artery Disease* Tina Constantin, MD, Jeremy R. Anthony,

An assessment by the Statin Intolerance Panel: 2014 update

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Epidemiology of opportunistic infections in AIDS patients

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Imaging for the Management of Community-Acquired Pneumonia

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Refurbishing Mayo Clinic Proceedings:

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Best Practices for Patients With Chronic Migraine

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

News & Notes Journal of Allergy and Clinical Immunology

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

W. Michael Hooten, MD, Michelle O. Kinney, MD, Marc A. Huntoon, MD

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

News & Notes Journal of Allergy and Clinical Immunology

Jann B. Skelton, Mitchel C. Rothholz, Parisa Vatanka

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Table of contents The Journal for Nurse Practitioners

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Direct Observation of Residents: A Model for an Assessment System

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

News & Notes Journal of Allergy and Clinical Immunology

Mayo Clinic Proceedings 2012: “A New Era in Journal Stewardship”

Presentation transcript:

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli M. Roth, MD, Maja Bujas-Bobanovic, Michael Louie, Bertrand Cariou Journal of Clinical Lipidology Volume 9, Issue 3, Pages 420-421 (May 2015) DOI: 10.1016/j.jacl.2015.03.027 Copyright © 2015 Terms and Conditions

Figure 1 Study Structure and flow. Journal of Clinical Lipidology 2015 9, 420-421DOI: (10.1016/j.jacl.2015.03.027) Copyright © 2015 Terms and Conditions

Figure 2 Physician and Patient Usability Statements Tested (Agree/Disagree). Journal of Clinical Lipidology 2015 9, 420-421DOI: (10.1016/j.jacl.2015.03.027) Copyright © 2015 Terms and Conditions